|
|
| Implementing Medium And High-Volume Drug Handling And Packaging Programs | Developing a combination drug–delivery product extends far beyond drug development. Pharmaceutical companies must decide whether to use an existing device platform or create a custom solution. While bespoke devices can improve performance and differentiation, they require managing design, manufacturing, assembly, combination product integration, packaging, serialization, release testing, and regulatory compliance. Successfully coordinating these activities is essential before products can enter clinical trials or reach patients in hospitals or home settings. Learn more. |
|
|
|
Webinar | Abzena | Selecting the right cell line platform is complex. Learn how flexible strategies, integrated technologies, and expert workflows enable high productivity, rapid timelines, and a de-risked path to clinical success. |
|
|
|
Webinar | KBI Biopharma | Integrated company solutions streamline drug substance to fill-finish transitions, resolving quality challenges, reducing delays, and accelerating timelines through coordinated processes and strategies. |
|
|
|
Video | Upperton Pharma Solutions | Optimizing small molecule development requires aligning formulation science with GMP manufacturing. Assimilate how phase-appropriate development, spray drying, and specialized oral and topical capabilities systematically compress clinical timelines and de-risk complex pipelines. |
|
|
|
Video | West Pharmaceutical Services, Inc. | See how our Synchrony S1 pre-fillable syringe system delivers an integrated, system-level solution designed for performance, quality, and scalability — with simplified submissions, synchronized supply, and compatibility across the drug delivery ecosystem. |
|
|
|
Video | Outsourced Pharma | This segment of the Outsourced Pharma Live event, “ADC Outsourcing: Plan Smart Now Or Suffer Later,” addresses where ADC sponsors most often misjudge complexity across the value chain, especially bioconjugation and analytical development. Ben explains why each ADC brings its own chemistry, payload, and molecule-specific behavior, and why analytical method development, transfer, and control strategy cannot be treated as secondary timeline items. Featuring Benjamin Hutchins, Ph.D., Founder & Principal Consultant, First Principles CMC. |
|
|
|
Video | Flamma | Backed by decades of chemistry expertise, this organization emphasizes technical rigor, transparency, and responsiveness to support long-term partnerships. |
|
|
| Connect With Outsourced Pharma: |
|
|
|